3-19 Kasuga-cho
Ashiya 659-0021
Japan
81 7 9732 8591
https://www.jcrpharm.co.jp
Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Shin Ashida | Chairman, CEO & President | N/A | N/A | 1943 |
Yoshihiro Ota | Director of Accounting Department & Corporate Strategy Department (Finance) | N/A | N/A | N/A |
Yutaka Honda | Senior Corporate Officer, Executive Director of Administration Div. & Director of Human Resources | N/A | N/A | N/A |
Hiroyuki Fukuya | Director of Legal Affairs Department - Administration Division | N/A | N/A | N/A |
Toru Ashida | Senior VP of Sales & Administration, Executive Director of Sales Division and Director | N/A | N/A | 1968 |
Ryutaro Makino | Director of Marketing Dept. & Group Manager of Product Planning - Marketing Dept. for Sales Div. | N/A | N/A | N/A |
Katsuya Nishino | Executive Vice President | N/A | N/A | 1956 |
Hiroshi Yoshimoto | Senior Advisor | N/A | N/A | 1951 |
Takayo Egawa | Corporate Officer & Director of International Affairs Office | N/A | N/A | N/A |
Mr. Hiroyuki Sonoda Ph.D. | VP of Research & Corporate Strategy, Executive Director of Research Division and Director | N/A | N/A | 1978 |
JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells, imports, and exports medical devices and laboratory instruments; and purchases and sells medical and research equipment. The company has a collaboration agreement with Angelini Pharma for the development of novel biologic therapies; and a. joint research agreement with Modalis Therapeutics Corporation to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.
JCR Pharmaceuticals Co., Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.